Plx Pharma Inc.

PLXPCIK 0001497504 · Every Form 4 filed by insiders at this issuer. See financials →

Annual report (10-K)

Latest 10-K/A filed Apr 29, 2022. Sentiment + YoY language diff vs prior year. Read sections →

Signal:NeutralFull-doc fallback

Full filing:tone 0.0023

Sentiment via Loughran-McDonald lexicon · YoY diff via Jaccard similarity + paragraph set difference.

YoY shift: Unscored

Year-over-year tone shift - average net-tone change across Risk Factors and MD&A vs the prior 10-K.

Why YoY instead of absolute: the LM lexicon has ~6.6× more negative words than positive (legal/risk-disclosure language is heavy on hedging), so every 10-K reads bearish on raw tone. Year-over-year change strips that bias and surfaces the actual shift in management's framing.

Per-snippet highlights

Sentence-level sentiment highlighting with category and subcategory filters is coming once the snippet-scoring pipeline lands. For now, dig into the actual section text on the Sections tab.

Top insiders

Most active reporters at Plx Pharma Inc.

Name	Roles	Filings
Giordano Natasha	OfficerDirector	2
O'Connor Rita M	Officer	2
Balkema Gary S.	Director	1
Calhoun Kirk K	Director	1
Casale Robert	Director	1

Showing 1-5 of 7

Per pagePage 1 of 2Next

All filings

9 Form 4 / 4-A filings, newest first

Filed	Insider	Top transaction	Shares	Price	Value
Mar 16, 2022	O'Connor Rita M Chief Financial Officer	PPurchase	10,000	$3.66	$36,600
Mar 16, 2022	Giordano Natasha Chief Executive Officer · Director	PPurchase	4,100	$3.6529	$14,977
Feb 24, 2022	Balkema Gary S. Director	Holdings only	-	-	-
Feb 24, 2022	Calhoun Kirk K Director	Holdings only	-	-	-
Feb 24, 2022	Casale Robert Director	Holdings only	-	-	-

Showing 1-5 of 9